ATE439345T1 - Zwischenprodukte für die herstellung von harnstoffderivaten mit muskarinrezeptor- antagonistischer aktivität - Google Patents

Zwischenprodukte für die herstellung von harnstoffderivaten mit muskarinrezeptor- antagonistischer aktivität

Info

Publication number
ATE439345T1
ATE439345T1 AT04012859T AT04012859T ATE439345T1 AT E439345 T1 ATE439345 T1 AT E439345T1 AT 04012859 T AT04012859 T AT 04012859T AT 04012859 T AT04012859 T AT 04012859T AT E439345 T1 ATE439345 T1 AT E439345T1
Authority
AT
Austria
Prior art keywords
production
intermediate products
antagonistic activity
urea derivatives
receptor antagonistic
Prior art date
Application number
AT04012859T
Other languages
English (en)
Inventor
Mathai Mammen
David Oare
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of ATE439345T1 publication Critical patent/ATE439345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04012859T 1999-12-07 2000-12-07 Zwischenprodukte für die herstellung von harnstoffderivaten mit muskarinrezeptor- antagonistischer aktivität ATE439345T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45617099A 1999-12-07 1999-12-07

Publications (1)

Publication Number Publication Date
ATE439345T1 true ATE439345T1 (de) 2009-08-15

Family

ID=23811737

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04012859T ATE439345T1 (de) 1999-12-07 2000-12-07 Zwischenprodukte für die herstellung von harnstoffderivaten mit muskarinrezeptor- antagonistischer aktivität
AT00982493T ATE271039T1 (de) 1999-12-07 2000-12-07 Harnstoffderivate wirksam als muscarinrezeptor- antagonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00982493T ATE271039T1 (de) 1999-12-07 2000-12-07 Harnstoffderivate wirksam als muscarinrezeptor- antagonisten

Country Status (27)

Country Link
US (3) US6635764B2 (de)
EP (2) EP1457488B1 (de)
JP (1) JP2003516391A (de)
KR (1) KR100748150B1 (de)
CN (1) CN1271054C (de)
AT (2) ATE439345T1 (de)
AU (1) AU782232B2 (de)
BR (1) BR0015963A (de)
CA (1) CA2392030C (de)
CZ (1) CZ20021830A3 (de)
DE (2) DE60042762D1 (de)
EA (1) EA006437B1 (de)
ES (3) ES2329785T3 (de)
HK (1) HK1049483B (de)
HR (1) HRP20020574B1 (de)
HU (1) HUP0203677A2 (de)
IL (2) IL149289A0 (de)
IS (1) IS2191B (de)
MX (1) MXPA02005602A (de)
NO (1) NO323544B1 (de)
NZ (1) NZ518722A (de)
PL (1) PL364922A1 (de)
SK (1) SK7982002A3 (de)
UA (1) UA73543C2 (de)
WO (1) WO2001042213A1 (de)
YU (1) YU42402A (de)
ZA (2) ZA200204553B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
GB0108099D0 (en) * 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
AU2002345266B2 (en) 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
CN101239971B (zh) * 2003-02-14 2011-07-20 施万制药 联苯衍生物
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2005089380A2 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US20050026844A1 (en) * 2003-04-03 2005-02-03 Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
EP1618091A1 (de) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituierte azabicyclohexanderivate als antagonisten von muscarinrezeptoren
JP2006522787A (ja) 2003-04-11 2006-10-05 ランバクシー ラボラトリーズ リミテッド ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体
WO2005000826A1 (en) * 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
WO2005007645A1 (en) * 2003-07-11 2005-01-27 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
AR047759A1 (es) * 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
PE20050973A1 (es) * 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
WO2005080375A1 (en) * 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087737A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528413A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
US7265133B2 (en) * 2004-03-11 2007-09-04 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7501442B2 (en) * 2004-03-11 2009-03-10 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) * 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723112A1 (de) * 2004-03-11 2006-11-22 Theravance, Inc. Als antagonisten für den muscarinrezeptor geeignete biphenylverbindungen
EP1723110A1 (de) * 2004-03-11 2006-11-22 Theravance, Inc. Als antagonisten des muscarinrezeptors geeignete biphenylverbindungen
US7618936B2 (en) * 2004-05-21 2009-11-17 The Regents Of The University Of California Methods for treating and diagnosing cancer with WNT inhibitory Factor-1 (WIF-1)
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
JP2008517072A (ja) * 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤
JP2008521821A (ja) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
GB0503054D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
TWI372749B (en) * 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008538104A (ja) * 2005-03-10 2008-10-09 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
JP2008537931A (ja) * 2005-03-10 2008-10-02 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099032A1 (en) * 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1863490A2 (de) * 2005-03-28 2007-12-12 Vertex Pharmaceuticals Incorporated Muskarinische modulatoren
JP2008546695A (ja) * 2005-06-13 2008-12-25 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
US7973055B2 (en) * 2006-03-09 2011-07-05 Theravance, Inc. Crystalline forms of a biphenyl compound
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
EP2119716A4 (de) * 2007-02-09 2011-06-01 Astellas Pharma Inc Aza-verbrückte ringverbindung
US8017617B2 (en) * 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
EP2096105A1 (de) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. 4-(2-Amino-1-hydroxyethyl)Phenol-Derivate als Agonisten des b2-adrenergen Rezeptors
MX2011011156A (es) 2009-04-23 2011-11-04 Theravance Inc COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
BR112013009138A2 (pt) * 2010-10-20 2016-07-26 Chiesi Farma Spa composto, usos de um composto, composição farmacêutica, kit de componentes e dispositivos para inalação
JP6021616B2 (ja) * 2012-12-04 2016-11-09 株式会社アエタスファルマ ３−ピペラジニル−１−ピペリジニル−プロパン誘導体及びそれを含有してなる医薬組成物
KR101514320B1 (ko) * 2013-06-14 2015-04-22 재단법인 의약바이오컨버젼스연구단 신규한 암 예방 또는 치료용 약학적 조성물
US9951060B2 (en) 2014-06-06 2018-04-24 Astellas Pharma Inc. 2-acylaminothiazole derivative or salt thereof
PT3792260T (pt) 2018-05-08 2024-10-02 Nippon Shinyaku Co Ltd Compostos de azabenzimidazol e produtos farmacêuticos
US12065433B2 (en) * 2018-10-24 2024-08-20 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
CN113874361B (zh) * 2019-03-29 2024-07-12 医药生命融合研究团 具有抗癌活性的化合物及其制备方法
TW202132316A (zh) * 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
DE3402060A1 (de) 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4675326A (en) 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
CA2133083A1 (en) * 1992-03-31 1993-10-14 Alexander W. Oxford Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht antagonists
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU685225B2 (en) * 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
US5691323A (en) 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
EP0923374A1 (de) * 1996-07-01 1999-06-23 Sepracor, Inc. Verfahren und zusammensetzungen zur behandlung von harninkontinenz mit enantiomerisch angereichertem (s)-trihexyphenidyl
US6500934B1 (en) 1996-07-24 2002-12-31 Michael Rush Lerner Bivalent agonists for G-protein coupled receptors
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6062766A (en) * 1997-08-04 2000-05-16 Quixote Corporation Raised pavement marker
CA2313125A1 (en) * 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
US6086881A (en) * 1998-05-15 2000-07-11 Children's Medical Center Corp. Spatially aligned conjugated composition having a thioether bond linkage
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
DE60021282T2 (de) * 1999-12-07 2006-05-18 Theravance, Inc., South San Francisco Carbamat-derivate als muscarin-rezeptor antonisten
WO2001098458A2 (en) * 2000-06-19 2001-12-27 Zyomyx, Inc. Methods for immobilizing polypeptides

Also Published As

Publication number Publication date
DE60042762D1 (de) 2009-09-24
US20020049195A1 (en) 2002-04-25
NZ518722A (en) 2004-03-26
SK7982002A3 (en) 2002-12-03
NO20022683L (no) 2002-07-02
IS2191B (is) 2007-01-15
PL364922A1 (en) 2004-12-27
BR0015963A (pt) 2002-08-06
EP1457488B1 (de) 2009-08-12
ES2225275T3 (es) 2005-03-16
ZA200204557B (en) 2003-09-08
ES2243333T3 (es) 2005-12-01
DE60012223T2 (de) 2005-08-25
CN1271054C (zh) 2006-08-23
US6635764B2 (en) 2003-10-21
UA73543C2 (uk) 2005-08-15
ES2329785T3 (es) 2009-12-01
EP1235803B1 (de) 2004-07-14
HRP20020574A2 (en) 2005-08-31
HUP0203677A2 (hu) 2003-03-28
KR100748150B1 (ko) 2007-08-09
CN1407970A (zh) 2003-04-02
WO2001042213A1 (en) 2001-06-14
US20040116706A1 (en) 2004-06-17
NO323544B1 (no) 2007-06-11
HK1049483A1 (en) 2003-05-16
EA200200646A1 (ru) 2002-12-26
NO20022683D0 (no) 2002-06-06
DE60012223D1 (de) 2004-08-19
YU42402A (sh) 2006-01-16
US20040054187A1 (en) 2004-03-18
JP2003516391A (ja) 2003-05-13
EP1235803A1 (de) 2002-09-04
CA2392030C (en) 2009-08-18
IL149289A (en) 2007-05-15
HK1049483B (en) 2005-02-18
EA006437B1 (ru) 2005-12-29
CA2392030A1 (en) 2001-06-14
IL149289A0 (en) 2002-11-10
KR20020058083A (ko) 2002-07-12
ATE271039T1 (de) 2004-07-15
AU782232B2 (en) 2005-07-14
MXPA02005602A (es) 2004-09-10
EP1457488A1 (de) 2004-09-15
HRP20020574B1 (hr) 2007-12-31
CZ20021830A3 (cs) 2002-10-16
AU1951801A (en) 2001-06-18
IS6362A (is) 2002-04-26
ZA200204553B (en) 2003-09-08

Similar Documents

Publication Publication Date Title
ATE439345T1 (de) Zwischenprodukte für die herstellung von harnstoffderivaten mit muskarinrezeptor- antagonistischer aktivität
ATE264856T1 (de) Heterocyclisch substituierte benzolderivate und herbizide
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
DE60027015D1 (en) Pseudoerythromycin-derivate
EP1566384A4 (de) Neue azolderivate
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
EP1643984A4 (de) Verwendung von parthenolid-derivaten als antileukämische und zytotoxische mittel
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
BRPI0108990B8 (pt) processo para preparação de derivados de pirimidona com atividade antifungos
BR0213990A (pt) Derivados de piperazina tendo atividade antagonìstica de sst1
EP1473295A4 (de) Kondensierte bicyclische pyrimidinderivate
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
DE60017374D1 (de) Antibakterielle mittel
ATE270671T1 (de) Zwischenprodukte für die herstellung von naphthyridin-3-carbonsäure-derivaten
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
BR9503845A (pt) Processo para a preparação de um composto e composto obtido
ATE405555T1 (de) Medizinische zusammensetzung, die ein 1,3- thiazinderivat enthält
DE69912193D1 (de) Substituierte 2-Hydroxybenzophenone, ihre Herstellung, ihre Verwendung als fungizide und ihre fungizide Zusammensetzungen
PT1072601E (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
DE60227655D1 (de) Pyrrolderivat
DE60315626D1 (de) Kondensierte bicyclische pyrimidinderivate
ATE340157T1 (de) Zwischenprodukte, verfahren für deren herstellung und deren gebrauch

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties